Thank you!
I fear, unfortunately, that most of these are precisely the points that those involved least want to hear - they do not want to spend money on anything that isn't going to bring results by the next election, they do not want Long COVID to have anything to do with ME/CFS (which they either don't believe in or which they see, quite correctly, as an indication of how intractable the problem really is, a fact they don't want to face), and they are pretty allergic to complexity of any sort. Of course, this has been true everywhere for a long time, so I suppose the matter is how to present the advice in a manner that won't result in immediate dismissal...
Dara (perhaps expanding this to the larger class of drugs / potential mechanism of action) seems like a real possibility; at the very least, it's the type of thing they want to hear. I don't know much about the funding structure wrt the NIH, but getting the name(s) in his ear in case an opportunity comes up absolutely seems worthwhile. It probably won't be much, I will see what I can do.